Network Medicine Approaches for Deciphering the Molecular Mechanisms of Natural Product-Based Cancer Therapy
Keywords:
network medicine; natural products; cancer therapy; molecular networks; polypharmacology; systems pharmacology; data governance; reproducibilityAbstract
Natural products have long contributed to cancer therapeutics, but their molecular mechanisms frequently remain difficult to characterize because they act through multiple targets and complex biological networks. Network medicine offers a system-level framework for interpreting these mechanisms by locating natural product targets within the global human interactome and by associating therapeutic effects with disease modules. This paper examines network medicine as an interpretive and operational architecture for natural product-based cancer therapy. It discusses how molecular network construction, community detection, and integrative data resources can clarify the polypharmacological action of natural products. The analysis emphasizes structural trade-offs among network coverage, precision, and causal interpretability, as well as the influence of missing data and false interactions on mechanistic claims. Governance, standardization, and reproducibility infrastructure are considered from the perspective of building durable and transparent research systems. The paper further addresses translational deployment in clinical decision support, focusing on robustness, uncertainty communication, and modular auditing. Fairness and policy implications are analyzed in relation to population heterogeneity, traditional knowledge, natural product sourcing, and sustainable data commons. The discussion integrates perspectives from network science, pharmacogenomics, toxicogenomics, and data governance to provide a long-form systems research account. Rather than centering on a single algorithm or finding, the paper foregrounds the design requirements for responsibly using network medicine to decipher natural product mechanisms and support cancer therapy development.
References
1. Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011). Network medicine: a network-based approach to human disease. Nature Reviews Genetics, 12(1), 56–68.
2. Hopkins, A. L. (2008). Network pharmacology: the next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682–690.
3. Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007). Drug–target network. Nature Biotechnology, 25(10), 1119–1126.
4. Newman, M. E. J. (2006). Modularity and community structure in networks. Proceedings of the National Academy of Sciences, 103(23), 8577–8582.
5. Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013). Structure and dynamics of molecular networks: A novel paradigm of drug discovery. Pharmacology & Therapeutics, 138(3), 333–408.
6. Kibble, M., Saarinen, N., Tang, J., Wennerberg, K., Mäkelä, S., & Aittokallio, T. (2015). Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Natural Product Reports, 32(8), 1249–1266.
7. Li, S., & Zhang, B. (2013). Traditional Chinese medicine network pharmacology: theory, methodology and application. Chinese Journal of Natural Medicines, 11(2), 110–120.
8. Menche, J., Sharma, A., Kitsak, M., Ghiassian, S. D., Vidal, M., Loscalzo, J., & Barabási, A.-L. (2015). Uncovering disease-disease relationships through the incomplete interactome. Science, 347(6224), 1257601.
9. Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products, 83(3), 770–803.
10. Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: advances and opportunities. Nature Reviews Drug Discovery, 20(3), 200–216.
11. Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., Reich, M., Hieronymus, H., Wei, G., Armstrong, S. A., Haggarty, S. J., Clemons, P. A., Wei, R., Carr, S. A., Lander, E. S., & Golub, T. R. (2006). The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science, 313(5795), 1929–1935.
12. Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., Lahr, D. L., Hirschman, J. E., Liu, Z., Donahue, M., Julian, B., Khan, M., Wadden, D., Smith, I. C., Lam, D., ... Golub, T. R. (2017). A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell, 171(6), 1437–1452.
13. Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., Jensen, L. J., & Mering, C. V. (2019). STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research, 47(D1), D607–D613.
14. Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., ... Wilson, M. (2018). DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Research, 46(D1), D1074–D1082.
15. Wang, Yinyin, et al. "HerbSyner_Finder: a network community-based model for identifying synergistic combinations from herbal medicines and complex systems." Targetome 2.2 (2026).
16. Cheng, F., Kovács, I. A., & Barabási, A.-L. (2019). Network-based prediction of drug combinations. Nature Communications, 10, 1197.
17. Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., Cokelaer, T., Greninger, P., van Dyk, E., Chang, H., de Silva, H., Heyn, H., Deng, X., Egan, R. K., Liu, Q., ... Garnett, M. J. (2016). A landscape of pharmacogenomic interactions in cancer. Cell, 166(3), 740–754.
18. Davis, A. P., Grondin, C. J., Johnson, R. J., Sciaky, D., McMorran, R., Wiegers, J., Wiegers, T. C., & Mattingly, C. J. (2019). The Comparative Toxicogenomics Database: Update 2019. Nucleic Acids Research, 47(D1), D948–D954.
19. Block, K. I., Gyllenhaal, C., Lowe, L., Amedeo, A., Amin, A. R. M. R., Amin, A., Aquilina, I., Arbiser, J., Arreola, A., Arzumanyan, A., Ashraf, S., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A., Bishayee, A., Blain, S. W., Block, P. B., Boosani, C. S., ... Zylstra, D. (2015). Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 35, S276–S304.
20. Haibe-Kains, B., El-Hachem, N., Birkbak, N. J., Jin, A. C., Beck, A. H., Aerts, H. J. W. L., & Quackenbush, J. (2013). Inconsistency in large pharmacogenomic studies. Nature, 504(7480), 389–393.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 International Journal of Clinical and Translational Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
This article is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
